Kisspeptin
Phase 2Small molecule
Kisspeptin is one of 11 small molecule programs targeting Hypogonadotropic Hypogonadism. It is currently in Phase 2.
3
Indications
13
Total Trials
3
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Amenorrhea
#DrugCompanyPhaseTrials
1Glucophage
EMD SeronoApproved
Zometa
PfizerPhase 3
Romosozumab
AmgenPhase 3
Cytotec
PfizerPreclinical
Kisspeptin
MMassachusetts General Hospital
Phase 2
Kisspeptin 112-121
SStephanie B. Seminara, MD
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
ISS2 trials
Dampening the Reproductive Axis With Continuous Kisspeptin
Completed·—·Phase 1·NCT05971849·8 enrolled
Reproductive Disorder2 trials
Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders
Completed·—·Phase 1·NCT05633966·13 enrolled
Hypogonadotropic Hypogonadism2 trials
Acute Lymphoblastic Leukemia1 trial
Recall by Genotype: Neuropeptide Stimulation
Terminated·—·Phase 1·NCT05901467·16 enrolled
5 more indications
Insulin Secretion1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Kisspeptin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- MMassachusetts General Hospital